Cytoo Announces Venture Partnership with PharmaNest to Launch 2D+ in the USA

Online, April 3, 2012 (Newswire.com) - CYTOO Inc, the US subsidiary of CYTOO SA, FRANCE, is pleased to announce a partnership with PharmaNest, Princeton, NJ, a contract operations organization who commercializes breakthrough International IND-Enabling Technologies and Services for the US Markets.

CYTOO develops products for cellular analysis and high-content cell screening. CYTOO's innovative 2D+ Cell Culture Platform is based on the use of micro-patterns on plates to enable major improvements in culturing cells. 2D+ increases assay reproducibility/reliability and improves the capacity to achieve a more physiological phenotype in cells cultured on 2D surfaces without resorting to a 3D culture system.

PharmaNest's experienced team is joining the CYTOO Inc team to provide larger visibility of the 2D+ Technology in North America and gather business efforts.

"2D+ is a new Dimension in Cell cultures and offers innovative options for Assay Optimization, Assay resuscitation (for instance, if you want to increase the Z' of an existing assay or reduce the consumption of precious and expensive cells). Importantly, it offers revolutionary means to quantify and/or drive the behavior of cells to enable new cell assays. The challenge of the commercialization of such innovative solutions is at the heart of what PharmaNest does well." said Matt Petitjean, Ph.D and President of PharmaNest.

"We are looking forward to increase our scientific visibility among the Pharmaceutical Industry while partnering with PharmaNest experts. Their scientific expertise and market knowledge are great added-values to our development in North America" said Pauline Menager, PhD Manager of Scientific Affairs at CYTOO.

About CYTOO
CYTOO focuses on innovative products for the life science research market with an emphasis in cell based assays, high content analysis and cell screening. The company has tailored a portfolio of innovative products using its proprietary cell adhesive micro-pattern technologies to target first its fast growing High Content Screening and Analysis segment within the large cell biology market.
www.cytoo.com